ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 2955 • 2018 ACR/ARHP Annual Meeting

    Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry

    Lene Dreyer1, Tine Iskov Kopp2, Rikke Kart Jacobsen3, Melinda Magyari2, Else Helene Ibfelt3, Henning Locht4, Finn Thorup Sellebjerg2, Dorte Vendelbo Jensen5 and René Cordtz6, 1Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, 2Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 3Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, 4Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, 5The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, 6Center for Rheumatology and Spine Diseases, Gentofte-Rigshospitalet, Hellerup, Denmark

    Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) have successfully been used for the treatment of immune-mediated inflammatory disorders including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
  • Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting

    How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry

    Sytske Anne Bergstra1, Lai-Ling Winchow2, Elizabeth Murphy3, Arvind Chopra4, Karen Salomon-Escoto5, João E. Fonseca6, Cornelia F. Allaart1 and Robert B.M. Landewé7, 1Department of Rheumatology, LUMC, Leiden, Netherlands, 2University of the Witwatersrand, Johannesburg, South Africa, 3University Hospital Wishaw, Scotland, Wishaw, United Kingdom, 4Center for Rheumatic Diseases, Pune, India, 5University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, 6Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 7Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands

    Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…
  • Abstract Number: 1186 • 2018 ACR/ARHP Annual Meeting

    Comparison of Biologic Discontinuation in Patients with Elderly-Onset Vs Younger-Onset Rheumatoid Arthritis

    Michael Richter1, Eric L. Matteson2, John M. Davis III2, Sara J. Achenbach3 and Cynthia S. Crowson3, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: Several studies have suggested that patients with elderly-onset rheumatoid arthritis (EORA) receive biologic treatments less frequently than patients with younger-onset RA (YORA). This has…
  • Abstract Number: 2206 • 2018 ACR/ARHP Annual Meeting

    Joint Repair While Initiating Biologic Therapy in Rheumatoid Arthritis

    Scott Brunet1,2,3, Sarah Manske1,2,3, Klaus Engelke4,5, Steven K. Boyd1,2,3 and Cheryl Barnabe2,6, 1Biomedical Engineering, University of Calgary, Calgary, AB, Canada, 2McCaig Institute for Bone and Joint Health, Calgary, AB, Canada, 3Department of Radiology, University of Calgary, Calgary, AB, Canada, 4Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany, 5Department of Medicine, Erlangen University Hospital, Erlangen, Germany, 6Division of Rheumatology, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Functional decline and reduced quality of life for patients with rheumatoid arthritis (RA) results from chronic changes to joints in patients, including bone erosions…
  • Abstract Number: 2591 • 2018 ACR/ARHP Annual Meeting

    Real-World Use of Secukinumab in Axial Spondyloarthritis: First Year Data from the Czech National Registry

    Herman F Mann1, Jakub Zavada2, Lucie Nekvindová3, Zlatuse Kristkova3, Pavel Horák4, Jiri Vencovsky1 and Karel Pavelka2, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, 4IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic

    Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with axial spondyloarthritis (AxSpA). This situation changed when anti-interleukin-17A…
  • Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting

    Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-

    Kosuke Ebina1, Makoto Hirao2, Motomu Hashimoto3, Wataru Yamamoto4, Akira Onishi5, Toru Hirano6, Ryota Hara7, Masaki Katayama8, Shuzo Yoshida9, Koji Nagai9, Yonsu Son10, Hideki Amuro10, Kengo Akashi11, Koichi Murata3, Kosaku Murakami12, Keiichi Yamamoto13 and Hideki Yoshikawa14, 1Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, 2Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, 5Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, 7The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, 8Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, 9Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, 10First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 11Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 12Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 13Department of Medical Statistics, Osaka City University, Osaka, Japan, 14Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan

    Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
  • Abstract Number: 1224 • 2018 ACR/ARHP Annual Meeting

    High Rates of Conversion and Reversion of Tuberculosis Screening Assays in Rheumatic Patients during Long Term Biologic Treatment

    Konstantinos Thomas1, Anastasia Makris1, Christina Tsalapaki1, Argyro Lazarini1, Kalliopi Klavdianou1, Katerina Antonatou1, Christos Koutsianas1, Chrisoula Hatzara1, Emilia Hadziyannis1 and Dimitrios Vassilopoulos2, 1Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, 2Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General HospitalMedicine, Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    Background/Purpose: Baseline screening for tuberculosis (TB) with tuberculin skin testing (TST) and/or interferon-gamma release assays (IGRAs) is recommended for all rheumatic patients starting biologic DMARDs…
  • Abstract Number: 2425 • 2018 ACR/ARHP Annual Meeting

    The Impact of Biologic Treatment for Rheumatoid Arthritis Patients Who Hope to Conceive

    Hiromi Shimada, Taichi Miyagi, Mikiya Kato, Risa Wakiya, Shusaku Nakashima, Tomohiro Kameda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: Previous reports revealed that it was difficult for rheumatoid arthritis (RA) patients to conceive1). Age, nulliparity, disease activity, NSAIDs, corticosteroid was known as the…
  • Abstract Number: 2592 • 2018 ACR/ARHP Annual Meeting

    Real-World Use of Secukinumab in Psoriatic Arthritis: First Year Data from the Czech National Registry

    Herman F Mann1, Jakub Zavada2, Lucie Nekvindová3, Zlatuse Kristkova3, Pavel Horák4, Jiri Vencovsky1 and Karel Pavelka2, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague 2, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 3Institute of Biostatistics and Analyses, Ltd., spinoff company of Masaryk University, Brno, Czech Republic, 4IIIrd Department of internal Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic

    Background/Purpose: Until recently, inhibitors of TNF (TNFi) had been the only bDMARD treatment option for patients with psoriatic arthritis (PsA). This situation changed when anti-interleukin-17A…
  • Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting

    Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis

    Josef S. Smolen1, Young Mo Kang2, Wan-Hee Yoo3, Paul Emery4, Michael E Weinblatt5, Edward C. Keystone6, Mark C. Genovese7, Gihyun Myung8, Evelyn Hong8, Inyoung Baek8 and Jeehoon Ghil8, 1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, 2Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), 3Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), 4University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 5Brigham and Women's Hospital, Boston, MA, 6Mount Sinai Hospital, Toronto, ON, Canada, 7Stanford University Medical Center, Palo Alto, CA, 8Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)

    Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
  • Abstract Number: 1386 • 2018 ACR/ARHP Annual Meeting

    Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)

    Christian Dejaco1, Thomas Mueller2, Omid Zamani, MD3, Ulrike Kurtz, MD4, Stefan Egger, MD5, Johannes Resch Passini, MD6, Anna Totzauer, MD7, Wolfgang Eisterer8, Babak Yazdani-Biuki, MD, Univ.Doc.9, Thomas Schwingenschloegl, MD10, Peter Peichl, MD. Univ.Doc. Msc11, Angelika Kraus12, Gerhard Naerr, PhD13 and Verena Rickert, MD. MBA14, 1Rheumatology and Immunology, Medical University Graz, Graz, Austria, 2Private Office Dr. Thomas Mueller, Graz, Austria, 3Rheuma Zentrum Favoriten, Vienna, Austria, 4Rheuma Praxis Dr. Kurtz, Gleisdorf, Austria, 5Ordination Gesundheitsquadrat, Vienna, Austria, 6Rheumatology Department, Rheuma-Zentrum Wien-Oberlaa GmbH, Vienna, Austria, 7Private Office Dr. Anna Totzauer, Gmuend, Austria, 8Department of Hematology and Internal Oncology, KLINIKUM- KLAGENFURT am WÖRTHERSEE, Klagenfurt, Austria, 9Dr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fuerstenfeld, Austria, 10Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria, 11Private Office Prim. Univ. Doz. Dr. Peter Peichl, MSc, Vienna, Austria, 12Private Office, Private Office Angelika Kraus, Melk, Austria, 13Medical Affairs, Merck Sharp & Dohme GmbH, Vienna, Austria, 14Medical Affairs, Merck Sharp&Dohme GmbH, Vienna, Austria

    Background/Purpose: Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic outcome data regarding patient‐reported outcomes and health economic parameters reflecting…
  • Abstract Number: 2444 • 2018 ACR/ARHP Annual Meeting

    The Risk of Solid Cancers in Patients with Rheumatoid Arthritis Exposed to Biologic Dmards with/without Prior Cancers

    Masaomi Yamasaki, Rheumatology, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

    Background/Purpose: To compare the risk of solid cancer in patient with rheumatoid arthritis treated with biologic disease modifying antirheumatic drugs(b-DMARDs) to that in patients treated…
  • Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders

    Jeffrey Crowley1, Kim A Papp2, Chih-ho Hong3, Jeff Parno4, Alan M Mendelsohn4, Qing Li5 and Nicole Cichanowitz5, 1Bakersfield Dermatology, Bakersfield, CA, 2Probity Medical Research, Waterloo, ON, Canada, 3University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, 5Merck & Co., Inc., Kenilworth, NJ

    Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
  • Abstract Number: 560 • 2018 ACR/ARHP Annual Meeting

    Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept

    Hafiz Oko-osi1, Machaon Bonafede2, Mahdi Gharaibeh1, Janna Manjelievskaia2, Lorena Lopez-Gonzalez2, David H. Collier1 and Bradley S. Stolshek1, 1Amgen Inc., Thousand Oaks, CA, 2IBM Watson Health, Cambridge, MA

    Background/Purpose:   Rheumatoid arthritis (RA) is a chronic disease that requires long-term treatment to improve or maintain disease activity.  Tumor necrosis factor inhibitors (TNFi), a…
  • Abstract Number: 1480 • 2018 ACR/ARHP Annual Meeting

    Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database

    Eishi Uechi1,2 and Kiyohide Fushimi2, 1Division of Rheumatology, Tomishiro Central Hospital, Okinawa, Japan, 2Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

    Background/Purpose: Pneumonia is the leading cause of mortality in RA patients. No research has been conducted on the prognosis of pneumonia in RA patients. This…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology